SMARCA4 and non-small cell lung carcinoma: As an inhibitor of the pro-oncogenic transcriptional coactivators, SMARCA4 is associated with increased metastatic incidence and leads to afatinib resistance in a patient with EGFR-mutant NSCLC (36, 37).